Prostate Cancer Subgroup May Benefit From Intensified Therapy

In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.
Medscape Medical News